On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy

Medical Dosimetry

Volumn 35, Issue 4, 2010, Pages 297-303

  Hodge, C W ^a   Tomé, Wolfgang A ^a   Fain, S B ^a   Bentzen, S M ^a   Mehta, M P ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Functional imaging; Image guidance; Lung cancer; Magnetic resonance imaging; Radiotherapy

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FEASIBILITY STUDY; HUMAN; HYPERPOLARIZED HELIUM NUCLEAR MAGNETIC RESONANCE IMAGING; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; TREATMENT PLANNING;

HELIUM; HUMANS; ISOTOPES; LUNG; LUNG INJURY; MAGNETIC RESONANCE IMAGING; PULMONARY GAS EXCHANGE; RADIATION INJURIES; RADIATION PROTECTION; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 78049473840     PISSN: 09583947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meddos.2009.09.004     Document Type: Article

References (30)

1. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung. Cancer. 1999, 24:31-37.
2. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980, 45:2744-2753.
3. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat. Rev. Cancer. 2006, 6:702-713.
4. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer. Res. 2000, 6:2166-2174.
5. Gandara D.R., Chansky K., Albain K.S., et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group Study (S9504). Clin. Lung. Cancer. 2006, 8:116-121.
6. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma. Report of Radiation Therapy Oncology Group 83. J. Clin. Oncol. 1990, 8:1543-1555.
7. Saunders M., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering Committee. Radiother. Oncol. 1999, 52:137-148.
8. Nagata Y., Takayama K., Matsuo Y., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1427-1431.
9. Hoyer M., Roed H., Hansen A.T., et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:S128-S135.
10. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 2006, 24:4833-4839.
11. McGuire S.M., Zhou S., Marks L.B., et al. A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:1543-1552.
12. Christian J.A., Partridge M., Nioutsikou E., et al. The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. Radiother. Oncol. 2005, 77:271-277.
13. Seppenwoolde Y., Engelsman M., De Jaeger K., et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother. Oncol. 2002, 63:165-177.
14. Kauczor H.U., Hofmann D., Kreitner K.F., et al. Normal and abnormal pulmonary ventilation: Visualization at hyperpolarized He-3 MR imaging. Radiology. 1996, 201:564-568.
15. Musch G., Venegas J.G. Positron emission tomography imaging of regional lung function. Minerva. Anestesiol. 2006, 72:363-367.
16. de Lange E.E., Altes T.A., Patrie J.T., et al. Evaluation of asthma with hyperpolarized helium-3 MRI: Correlation with clinical severity and spirometry. Chest 2006, 130:1055-1062.
17. Fain S.B., Panth S.R., Evans M.D., et al. Early emphysematous changes in asymptomatic smokers: Detection with 3He MR imaging. Radiology 2006, 239:875-883.
18. Ireland R.H., Bragg C.M., McJury M., et al. Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:273-281.
19. Withers H.R., Taylor J.M., Maciejewski B. Treatment volume and tissue tolerance. Int. J. Radiat. Oncol. Biol. Phys. 1988, 14:751-759.
20. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:329-339.
21. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:672-682.
22. Deniaud-Alexandre E., Touboul E., Lerouge D., et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1432-1441.
23. Grills I.S., Yan D., Black Q.C., et al. Clinical implications of defining the gross tumor volume with combination of CT and (18)FDG-positron emission tomography in non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:709-719.
24. Kwa S.L., Lebesque J.V., Theuws J.C., et al. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:1-9.
25. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:650-659.
26. Kocak Z., Borst G.R., Zeng J., et al. Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:178-186.
27. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:318-328.
28. Larsen K.R., Lund J.O., Svendsen U.G., et al. Prediction of post-operative cardiopulmonary function using perfusion scintigraphy in patients with bronchogenic carcinoma. Clin. Physiol. 1997, 17:257-267.
29. Yaremko B.P., Guerrero T.M., Noyola-Martinez J., et al. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:562-571.
30. Jackson A., Kutcher G.J., Yorke E.D. Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation. Med. Phys. 1993, 20:613-625.